Immutep (ASX:IMM) has announced a new clinical trial collaboration under which the Australian company's investigative LAG-3 immunotherapy, efti, will be studied with Merck and Pfizer's PBS-listed BAVENCIO (avelumab). …
Immutep announces new collaboration for cancer treatment combination
November 29, 2022 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
Biogen ANZ certified a 'Great Place to Work' for a fifth time
October 16, 2026 - - Latest News -
Tavneos to be withdrawn from Australia as CSL pulls vasculitis treatment
October 16, 2026 - - Latest News -
AI in HTA - survey reveals optimism and concern over a potential missed opportunity
October 16, 2026 - - Latest News -
England's chief scientific officer on the opportunity for Australia to get it right on genomics
October 15, 2026 - - Latest News -
The medicines gap costing Australian children time they can't get back
October 15, 2026 - - Latest News -
Brain cancer advocates return to Canberra 'to keep that ambition alive'
October 15, 2026 - - Latest News -
The effort to change an institution from within, works best when exit is possible
October 15, 2026 - - Latest News